Pathogenic mutations in LRRK2 cause increased kinase activity which can lead to cellular demise (West et al., 2005; Greggio et al., 2006; Smith et al., 2006; Lee et al., 2010; Steger et al., 2016), highlighting that the kinase activity of LRRK2 may represent an important therapeutic PD target. This evidence concerns the gene LRRK2 and Parkinson disease.